SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to an earnings "double beat" and positive AI demand commentary, fueling optimism and sending shares higher after hours. The community is celebrating the results, anticipating further gains, and some speculate about government influence and potential short squeezes. Discussions include targets, the CEO's performance, and the broader implications for the semiconductor sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid speculation and conflicting reports about potential government equity stakes in quantum computing firms, driving volatility and high trading volume. The community is debating the validity and impact of the rumored deal, with some seeing it as a validation of the sector while others believe it's a pump and dump scheme. Broader discussions include the long-term potential of quantum computing and its significance in the global technology race.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its strategic partnership with Palantir to enhance enterprise AI capabilities and its potential role in the growing AI sector, particularly regarding data centers and fiber optic infrastructure. Community members are also anticipating upcoming earnings and speculating on potential acquisitions. The broader discussion revolves around Lumen's transformation and its position in the evolving tech landscape.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford ($F) is trending as investors react to potential tariff relief and strong Q3 sales figures, including a surge in EV sales, before the EV tax credit expires. Community members are discussing whether Ford can sustain this momentum, especially with a focus on management's plans and the potential for a breakout above the $12.50 resistance level. Some are also closely monitoring a news report regarding potential changes coming Monday.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber's stock is trending amid news of a collaboration with Nvidia to advance autonomous vehicle technology, sparking discussions about the company's strategic position and potential revenue streams in the evolving transportation sector; the community is analyzing the partnership's impact, especially in light of Uber's existing partnerships with EV manufacturers like Lucid and potential competition with Tesla. Some investors believe this could drive significant growth, while others express concern about immediate revenue impact and the stock's historical resistance to meaningful gains on news.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor (DECK) is experiencing share price volatility despite a recent earnings beat, leading to community discussion about potential reasons for the disconnect, including concerns about future guidance. Some traders point to significant call option activity, while others speculate on the impact of tariffs and broader retail sector trends. Despite strong brand performance with Hoka and UGG, investors are debating whether the current price represents a buying opportunity or reflects deeper concerns.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp ($NEM) is trending after posting strong quarterly earnings, exceeding analysts' estimates, which the community is calling a major beat. Bullish sentiment is growing as investors discuss cost-saving initiatives and rising gold prices potentially driving the stock higher. However, some traders are cautious, anticipating short-term pullbacks and profit-taking despite the positive results.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences ($VTYX) is trending due to recent Phase 2 trial results, sparking discussions around the drug's potential in treating obesity and cardiovascular risk factors. While some traders are optimistic about potential analyst upgrades and a possible buyout, others express concerns about a potential offering. Community members are actively debating entry and exit points, as well as speculating on future price movements and consolidation.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as investors discuss potential government contracts and insider trading after significant call option sweeps, specifically for the $27 strike price. Community members speculate about upcoming news related to rare earth minerals and uranium, driven by geopolitical tensions and a focus on domestic supply chains. While some traders express caution and highlight algorithmic trading patterns, bullish sentiment remains strong due to the company's strategic positioning in the sector.

BlackRock, Inc. engages in the provision of investment, advisory and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is trending as the community discusses institutional investment and potential short squeeze opportunities for a related stock, $BYND.  Traders are pointing to BlackRock's existing stake in $BYND, meme ETF inclusion, and upcoming earnings as potential catalysts. Some investors are also watching for a broader market momentum shift into BLK, highlighting its stability within the financial sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy

Sagimet Biosciences Inc. (SGMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical...

Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks

The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?

Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's  What You Should Know

Shares of Sagimet Biosciences soared nearly 40% on Monday, reaching levels not seen since March 2024, as retail sentiment surged following news of an upcoming presentation linked to its lead drug candidate.&nbsp;The clinical-stage biopharma company, which is developing novel therapeutics targeting metabolic and fibrotic diseases, announced that it will present at the 9th Annual MASH-TAG Conference in Park City, Utah, from Jan. 9&nbsp;to 11.The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase 2b FASCINATE-2 study for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMT_sentiment_and_message_volume_Jan_6_fc5e3fb3e0.png" alt="SGMT sentiment and message volume Jan 6.png" width="1318" height="324"><figcaption>SGMT sentiment and message volume Jan 6 as of 11:35 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish,’ with Sagimet’s stock trending among the top 20 tickers as of mid-morning.&nbsp;Many investors&nbsp;eagerly await further announcements at the conference, with some buying based on rumors of a significant update.<stembedurl>https://stocktwits.com/GXD_Texas/message/598950606</stembedurl><stembedurl>https://stocktwits.com/valueforme/message/598944787</stembedurl>The study demonstrated a positive anti-fibrotic effect, providing strong support for the drug’s potential in treating liver diseases caused by excessive fat buildup and inflammation.Sagimet’s FASN inhibitors aim to address the dysfunctional metabolic pathways responsible for the overproduction of palmitate, a fatty acid linked to diseases like MASH.&nbsp;Denifanstat’s progress has been noteworthy, with Breakthrough Therapy designation granted by the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis (F2-F3).Oppenheimer’s recent coverage of Sagimet with an ‘outperform’ rating and a $30 price target, which implies more than a 340% upside from current levels, has also contributed to the stock’s upward movement.&nbsp;The brokerage firm highlighted denifanstat’s potential in the MASH market, which is currently dominated by Madrigal Pharmaceuticals’ Resmetirom.&nbsp;Oppenheimer estimates denifanstat could achieve peak revenues of around $1.9 billion by 2040, solidifying its long-term growth prospects.<a href="https://stocktwits.com/symbol/SGMT">Sagimet stock</a> has gained nearly 50% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate

Many investors eagerly await further announcements at the conference, with some buying based on rumors of a significant update.

Equity

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily...

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Sagimet Biosciences, Inc. Class A (SGMT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies (LQDA Research Report) and Sagimet Biosciences, Inc. Class A...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMT News

SGMTSagimet Biosciences Inc